ATE330967T1 - An her2 bindende peptidverbindungen - Google Patents

An her2 bindende peptidverbindungen

Info

Publication number
ATE330967T1
ATE330967T1 AT00946990T AT00946990T ATE330967T1 AT E330967 T1 ATE330967 T1 AT E330967T1 AT 00946990 T AT00946990 T AT 00946990T AT 00946990 T AT00946990 T AT 00946990T AT E330967 T1 ATE330967 T1 AT E330967T1
Authority
AT
Austria
Prior art keywords
her2
novel compounds
peptide compounds
erbb2
provides
Prior art date
Application number
AT00946990T
Other languages
English (en)
Inventor
Mark S Dennis
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE330967T1 publication Critical patent/ATE330967T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
AT00946990T 1999-07-02 2000-06-30 An her2 bindende peptidverbindungen ATE330967T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14223299P 1999-07-02 1999-07-02

Publications (1)

Publication Number Publication Date
ATE330967T1 true ATE330967T1 (de) 2006-07-15

Family

ID=22499090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946990T ATE330967T1 (de) 1999-07-02 2000-06-30 An her2 bindende peptidverbindungen

Country Status (9)

Country Link
US (1) US6987088B2 (de)
EP (1) EP1189931B1 (de)
JP (2) JP4387625B2 (de)
AT (1) ATE330967T1 (de)
AU (1) AU779612C (de)
CA (1) CA2373721C (de)
DE (1) DE60028970T2 (de)
IL (2) IL147271A0 (de)
WO (1) WO2001001748A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) † 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7396810B1 (en) 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
WO2003061559A2 (en) * 2001-10-12 2003-07-31 University Of Vermont And State Agricultural College Binding peptides specific for the extracellular domain of erbb2 and uses therefor
NZ533126A (en) 2002-01-17 2006-04-28 Univ British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
DE10208877B4 (de) * 2002-03-01 2009-04-09 Erdmann, Volker A., Prof.Dr. Verwendung eines Streptavidin- Bindungspeptides
ATE450544T1 (de) 2002-03-01 2009-12-15 Volker A Erdmann Streptavidin-bindungspeptid
EP2902491A1 (de) 2003-03-19 2015-08-05 Biogen MA Inc. NOGO Rezeptor bindendes Protein
DE602004018141D1 (de) * 2003-07-04 2009-01-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
CA2560759A1 (en) * 2004-03-03 2005-12-22 Iq Corporation Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof
EP1758610B1 (de) * 2004-05-20 2012-07-04 ZymoGenetics, Inc. Verfahren zur behandlung von krebs mit il-21 und monoklonale antikörper-therapie
EP1776136B1 (de) 2004-06-24 2012-10-03 Biogen Idec MA Inc. Behandlung von entmyelinisierenden erkrankungen
ZA200701234B (en) * 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
AU2005294347A1 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
AU2006204459B2 (en) 2005-01-05 2012-11-01 F-Star Therapeutics Limited Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
MX2008000253A (es) 2005-07-08 2008-04-02 Biogen Idec Inc Anticuerpos de sp35 y usos de los mismos.
JP2009511060A (ja) * 2005-10-14 2009-03-19 バイオレクシス ファーマシューティカル コーポレーション ナトリウム利尿ペプチド修飾されたトランスフェリン融合タンパク質
EP2543384A3 (de) 2005-12-02 2013-04-10 Biogen Idec MA Inc. Behandlung von Zuständen mithilfe von Demyelinisation
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
CN101522717A (zh) * 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
WO2008150485A2 (en) * 2007-05-29 2008-12-11 Wyeth Erbb2 binding proteins and use thereof
CN101802006B (zh) 2007-06-26 2013-08-14 F-星生物技术研究与开发有限公司 展示结合剂
US20100297121A1 (en) * 2007-10-11 2010-11-25 Biogen Idec Ma Inc. Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
AU2008325107B2 (en) * 2007-11-08 2015-04-23 Biogen Ma Inc. Use of LINGO-4 antagonists in the treatment of conditions involving demyelination
EP2113255A1 (de) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Zytotoxisches Immunglobulin
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
EP2145901B1 (de) 2008-07-18 2012-11-14 Technische Universität Braunschweig Rekombinante anti-MUC1-Antikörper
JP2013531474A (ja) 2010-04-30 2013-08-08 エスペランス ファーマシューティカルズ， インコーポレイテッド 溶解性ペプチド−Ｈｅｒ２／ｎｅｕ（ヒト上皮成長因子レセプター２）リガンド結合体およびその使用方法
ES2598829T3 (es) * 2011-03-28 2017-01-30 S.I.S. Shulov Innovative Science Ltd. Procedimiento de tratamiento de trastornos cutáneos
PL2726092T3 (pl) 2011-06-28 2019-11-29 Inhibrx Lp Polipeptydy fuzyjne serpiny i sposoby ich stosowania
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
KR102142161B1 (ko) 2012-05-14 2020-08-06 바이오젠 엠에이 인코포레이티드 운동 뉴런 관련 병태 치료용 lingo-2 길항제
WO2015138452A1 (en) 2014-03-11 2015-09-17 Molecular Templates, Inc. Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
SG11201608192SA (en) 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
RS60441B1 (sr) 2015-05-30 2020-07-31 Molecular Templates Inc De-imunizovane, strukture shiga toksin a podjedinice i ciljani ćelijski molekuli koji sadrže isti
HK1248258A1 (zh) 2015-07-26 2018-10-12 Molecular Templates, Inc. 包含志贺毒素a亚基效应物和cd8+ t-细胞表位的细胞靶向分子
WO2017200787A1 (en) 2016-05-18 2017-11-23 Arizona Board Of Regents On Behalf Of Arizona State University Peptide-dna chimeras for treatment of her overexpressing cancers
US10576082B2 (en) 2016-09-06 2020-03-03 Academia Sinica ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in alzheimer's disease
WO2018140427A1 (en) 2017-01-25 2018-08-02 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
IL268443B2 (en) 2018-04-17 2024-07-01 Molecular Templates Inc HER2-targeted molecules containing Shiga toxin subunit A scaffolds, without vaccination

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5578482A (en) * 1990-05-25 1996-11-26 Georgetown University Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses
US5279966A (en) * 1992-04-02 1994-01-18 The Trustees Of Columbia University In The City Of New York Cloning, expression and uses of a novel secreted protein, F-spondin
US5871969A (en) * 1996-02-12 1999-02-16 Human Genome Sciences, Inc. Nucleic acids encoding human neuronal attachment factor-1
KR100628846B1 (ko) * 1996-10-18 2006-09-29 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
CA2295317A1 (en) * 1997-06-17 1998-12-23 Human Genome Sciences, Inc. Heregulin-like factor
AU4469997A (en) * 1997-09-17 1999-04-05 Urs Eppenberger Heregulin-gamma
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JP4485051B2 (ja) * 1998-02-04 2010-06-16 ジェネンテック， インコーポレイテッド 上皮細胞増殖因子としてのヘレグリンの用途
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists

Also Published As

Publication number Publication date
IL147271A (en) 2014-07-31
AU779612B2 (en) 2005-02-03
US20030171278A1 (en) 2003-09-11
US6987088B2 (en) 2006-01-17
CA2373721A1 (en) 2001-01-11
DE60028970T2 (de) 2007-02-15
EP1189931A2 (de) 2002-03-27
AU779612C (en) 2005-12-15
DE60028970D1 (de) 2006-08-03
CA2373721C (en) 2013-10-15
EP1189931B1 (de) 2006-06-21
JP4387625B2 (ja) 2009-12-16
JP2010004885A (ja) 2010-01-14
AU6066900A (en) 2001-01-22
JP2003503075A (ja) 2003-01-28
IL147271A0 (en) 2002-08-14
WO2001001748A2 (en) 2001-01-11
WO2001001748A3 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
ATE330967T1 (de) An her2 bindende peptidverbindungen
AU2002305450A1 (en) Proteomimetic compounds and methods
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
GB0222495D0 (en) Compounds
WO2004047728A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004039956A3 (en) Compositions and methods for the treatment of immune related diseases
AU3368497A (en) Human dnase i hyperactive variants
IL173348A (en) Thienopyridine compounds, pharmaceuticals containing them and their use in the preparation of drugs
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
ATE514718T1 (de) Peptabody für krebsbehandlung
WO2004076614A3 (de) Humane nukleinsäuresequenzen aus prostatakarzinomen
IL154522A0 (en) IgE RECEPTOR ANTAGONISTS
WO2003102185A3 (en) Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
IL207012A (en) 28sgp medicinal product and 28sgp accent cancer treatment vaccine
EA200600995A1 (ru) Молекулы, ингибирующие ангиогенез, и их применение в лечении и диагностике рака
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004031354A3 (en) Human sarcoma-associated antigens
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
WO2003080624A3 (en) Dithiolopyrrolone derivatives useful in the treatment of proliferative diseases
WO2004004649A3 (en) Compositions and methods for the treatment of immune related diseases
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties